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Hepatocellular Carcinoma (HCC) is endemic in Asia. It is expected 
that about 80% of new HCC cases worldwide will develop in Asia 
[1,2]. Screening programs improve the detection of early HCC and 
have a positive impact on survival, but the majority of HCC patients 
in Asia still present with advanced stage disease. Although surgical 
resection is generally accepted as the most effective treatment for HCC, 
most patients with advanced HCC are not suitable candidates for 
surgical treatment at the time of diagnosis because of extensive tumor 
involvement of the liver, vascular invasion, intrahepatic or extrahepatic 
spread as well as poor liver function. Therefore, unfortunately most 
patients are eligible for only palliative treatments.
The treatment outcomes of HCC are affected by various factors, 
including liver function, performance status of the patient and tumor 
stage. For optimal management, the treatment choice is guided by 
staging systems and treatment guidelines. To date, several staging 
systems and treatment guidelines have been proposed for each 
region. According to the Barcelona Clinic Liver Cancer guideline 
based on evidence from randomized clinical trials, only Transarterial 
Chemoembolization (TACE) is recommended for intermediate stage 
and sorafenib for advanced stage [3-5]. However, treatment guidelines 
from Asian countries have adopted several other therapeutic modalities 
such as a surgical approach, hepatic arterial infusion chemotherapy, 
external radiation, and their combinations based on clinical experiences 
for intermediate and advanced stage HCC. 
In the intermediate stage, although TACE is the main therapeutic 
modality of it, overall therapeutic outcomes depend on the tumor 
size. When HCCs are larger than 3 cm, complete necrosis is seldom 
observed through TACE [6,7]. To improve loco-regional therapies 
for patients with unresectable HCC, new liver-directed therapies have 
emerged. Preliminary results of the use of Drug-Eluting Beads (DEBs) 
suggest that this approach is associated with a favorable toxicity profile 
and encouraging antitumor activity [8-10]. In a recent study comparing 
conventional TACE with DEB-TACE, the DEB-TACE group resulted 
in a compatible local response, fewer recurrences, lower side effect and a 
longer time to progression compared to the conventional TACE group 
[11]. Radioembolization with Yttrium-90-embedded microspheres is 
a new method suggesting an effective treatment approach for patients 
with unresectable HCC [12]. TACE followed by Radio Theraphy (RT) 
has been reported to improve tumor response and overall survival 
over TACE alone [13]. Localized concurrent chemoradiation therapy 
followed by repetitive hepatic arterial infusional chemotherapy in 
locally advanced HCC has shown promising results [14,15]. Therefore, 
combinations of local regional treatments along with sorafenib which 
is the standard care of advanced stage HCC, might be also considered 
in the advanced stage, according to the tumor status, e.g. major vessel 
invasion or extra hepatic spread.
There are still many therapeutic options aside from sorafenib for 
the locally advanced stage based on Asian experts’ opinions. Despite 
the concentrated efforts of all kinds of medical specialties to improve 
survival, the results have still achieved limited success. Therefore, a 
multidisciplinary approach may be mandatory to improve patients’ 
survival by inter-department cooperation. And multidisciplinary 
approach for the management of HCC may overcome current barrier 
and improve therapeutic efficacy leading to improve survival in the 
near future.
References
1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J (2010) Cancer Incidence 
in Five Continents. Lyon, IARC.
2. Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, et al. (2010) Liver Cancer 
Working Group Report. Jpn J Clin Oncol 40: i19–i27.
3. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in 
hepatocellular carcinoma. Hepatology 35: 519–524.
4. Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and 
treatment: the BCLC update and future prospects. Semin Liver Dis 30: 61–74.
5. Marrero JA, Kudo M, Bronowicki JP (2010) The challenge of prognosis and 
staging for hepatocellular carcinoma. Oncologist 15: 23–33.
6. Han KH, Lee JT, Seong J (2002) Treatment of nonresectable hepatocellular 
carcinoma. J Gastroenterol Hepatol 17: S424–S427.
7. Shim SJ, Seong J, Han KH (2005) Local radiotherapy as a complement to 
incomplete transcatheter arterial chemoembolization in locally advanced 
hepatocellular carcinoma. Liver Int 25: 1189–1196.
8. Malagari K, Chatzimichael K, Alexopoulou E (2008) Transarterial 
chemoembolization of unresectable hepatocellular carcinoma with drug eluting 
beads: results of an open-label study of 62 patients. Cardiovasc Intervent 
Radiol 31: 269–280.
9. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, et al. (2007) A phase I/ II trial 
of chemoembolization for hepatocellular carcinoma using a novel intra-arterial 
drug-eluting bead. Clin Gastroenterol Hepatol 5: 1100–1108.
10. Varela M, Real MI, Burrel M, Forner A, Sala M, et al. (2007) Chemoembolization 
of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin 
pharmacokinetics. J Hepatol 46: 474–481.
11. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, et al. (2010) Prospective 
randomized study of doxorubicin-eluting- bead embolization in the treatment 
of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc 
Intervent Radiol 33: 41–52.
12. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, et al. (2010) 
Citation: Shim CN, Park JY (2013) A Multidisciplinary Approach for the Treatment of Intermediated to Advanced Hepatocellular Carcinoma – Is it Still 
Optional? J Liver 2: e105. doi:10.4172/2167-0889.1000e105
Page 2 of 2
Volume 2 • Issue 2 • 1000e105
J Liver 
ISSN: 2167-0889 JLR, an open access journal 
Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: 
a comprehensive report of long-term outcomes. Gastroenterology 138: 52–64.
13. Seong J, Park HC, Han KH, Lee DY, Lee JT, et al. (2000) Local radiotherapy for 
unresectable hepatocellular carcinoma patients who failed with transcatheter 
arterial chemoembolization. Int J Radiat Oncol 47: 1331–1335.
14. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, et al. (2007): Repetitive short-
course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and 
cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110:129-
137.
15. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, et al. (2008) Pilotclinical trial of 
localized concurrent chemoradiation therapy for locally advanced hepatocellular 
carcinoma with portal vein thrombosis. Cancer 113: 995–1003.
Submit your next manuscript and get advantages of OMICS 
Group submissions
Unique features:
•	 User	friendly/feasible	website-translation	of	your	paper	to	50	world’s	leading	languages
•	 Audio	Version	of	published	paper
•	 Digital	articles	to	share	and	explore
Special features:
•	 250	Open	Access	Journals
•	 20,000	editorial	team
•	 21	days	rapid	review	process
•	 Quality	and	quick	editorial,	review	and	publication	processing
•	 Indexing	at	PubMed	(partial),	Scopus,	EBSCO,	Index	Copernicus	and	Google	Scholar	etc
•	 Sharing	Option:	Social	Networking	Enabled
•	 Authors,	Reviewers	and	Editors	rewarded	with	online	Scientific	Credits
•	 Better	discount	for	your	subsequent	articles
Submit	your	manuscript	at:	http://www.omicsonline.org/submission
Citation: Shim CN, Park JY (2013) A Multidisciplinary Approach for the 
Treatment of Intermediated to Advanced Hepatocellular Carcinoma – Is it Still 
Optional? J Liver 2: e105. doi:10.4172/2167-0889.1000e105
